Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TX000045

Other · developed by Tectonic Therapeutic

Phase 2 Most advanced trial
TECX Developer
2 Registered trials

What is TX000045?

TX000045 is an investigational drug studied in Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary.

At a glance

Drug type
Other
Therapy area
Cardiovascular, Respiratory
Developer
Tectonic Therapeutic (TECX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07473700 Phase 2 Hypertension, Pulmonary Recruiting TECX
NCT06616974 Phase 2 Pulmonary Hypertension Active not recruiting TECX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart Failure With Preserved Ejection FractionHypertension, PulmonaryLung Diseases, InterstitialPulmonary Hypertension

More from Tectonic Therapeutic

TX002100 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TECX page.

Follow TECX, the company behind TX000045

See TECX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TECX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.